HYPERTENSION MANAGEMENT AND STROKE PREVENTION ...
HYPERTENSION MANAGEMENT AND STROKE PREVENTION ... HYPERTENSION MANAGEMENT AND STROKE PREVENTION ...
16 ALLHAT Decision to Drop an ALLHAT Arm • January 24, 2000 – NHLBI Director accepts the recommendation of an independent review group to terminate doxazosin arm – Futility of finding a significant difference for primary outcome – Statistically significant 25 percent higher rate of major secondary endpoint, combined CVD outcomes
17 Cumulative Event Rate 0.30 0.25 0.20 0.15 0.10 0.05 0.00 0 1 2 3 4 C: 15,268 D: 9,067 Cardiovascular Disease Rel Risk 1.25 doxazosin 12,990 7,382 95% CI 1.17-1.33 z = 6.77, p < 0.0001 chlorthalidone 9,443 5,285 Years of Follow-up ALLHAT 4,827 2,654 2,010 1,083 JAMA. 2000;283:1967-1975
- Page 1 and 2: HYPERTENSION MANAGEMENT AND STROKE
- Page 3 and 4: 3 Hypertension Treatment by Drug Cl
- Page 5 and 6: 5 ALLHAT Antihypertensive Trial Des
- Page 7 and 8: 7 ALLHAT Pre-Specified Outcomes All
- Page 9 and 10: 9 ALLHAT Inclusion Criteria for Ant
- Page 11 and 12: 11 ALLHAT ALLHAT Inclusion Criteria
- Page 13 and 14: 13 ALLHAT High-risk hypertensive pa
- Page 15: 15 ALLHAT Step 2 Agents: Reserpine
- Page 19 and 20: 19 ALLHAT 100.0 80.0 60.0 % 40.0 20
- Page 21 and 22: 21 ALLHAT mm Hg BP 150 145 140 135
- Page 23 and 24: 23 Percent ALLHAT 80 60 40 20 0 59
- Page 25 and 26: 25 ALLHAT Cumulative Stroke Rate .1
- Page 27 and 28: 27 ALLHAT Cumulative Mortality Rate
- Page 29 and 30: 29 ALLHAT Total 1.04 (0.99, 1.09) A
- Page 31 and 32: 31 ALLHAT Total 1.38 (1.25, 1.52) A
- Page 33 and 34: 33 ALLHAT AHT: TOTAL CHD AND ALL CA
- Page 35 and 36: 35 ALLHAT Antihypertensive Trial: I
- Page 38 and 39: 38 ALLHAT vs. ANBP-2 • Randomized
- Page 40 and 41: Primary Adjudicated Events - Ramipr
- Page 42 and 43: DOES OBSERVED BP REDUCTION ACCOUNT
- Page 44 and 45: Quartiles ≤124 125-139 140-150 15
- Page 46 and 47: SUBGROUP RESULTS BY OTHER DRUG THER
- Page 48 and 49: 48 Blood Pressure Classification BP
- Page 50 and 51: 50 New Features and Key Messages
- Page 52 and 53: 52 New Features and Key Messages (C
- Page 54 and 55: 54 Algorithm for Treatment of Stage
16<br />
ALLHAT<br />
Decision to Drop<br />
an ALLHAT Arm<br />
• January 24, 2000 – NHLBI Director accepts<br />
the recommendation of an independent<br />
review group to terminate doxazosin arm<br />
– Futility of finding a significant difference<br />
for primary outcome<br />
– Statistically significant 25 percent higher<br />
rate of major secondary endpoint,<br />
combined CVD outcomes
Change language